They showed that treatment with SGLT2 inhibitors was associated with a significant reduction in the risk of SCD (odds ratio: 0.72; 95% confidence interval: 0.54–0.97) compared with that in the control group. The gene discussed is SLC5A2; the disease is Schnyder corneal dystrophy.